Compare · LNTH vs QUIT
LNTH vs QUIT
Side-by-side comparison of Lantheus Holdings Inc. (LNTH) and Achieve Life Sciences Inc. (QUIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNTH and QUIT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH is the larger of the two at $6.65B, about 10.0x QUIT ($666.8M).
- Over the past year, LNTH is up 93.6% and QUIT is up 36.7% - LNTH leads by 56.9 points.
- LNTH has been more active in the news (12 items in the past 4 weeks vs 1 for QUIT).
- LNTH has more recent analyst coverage (18 ratings vs 0 for QUIT).
- Company
- Lantheus Holdings Inc.
- Achieve Life Sciences Inc.
- Price
- -
- -
- Market cap
- $6.65B
- $666.8M
- 1M return
- +1.80%
- -9.09%
- 1Y return
- +93.60%
- +36.67%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 12
- 1
- Recent ratings
- 18
- 0
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Achieve Life Sciences Inc.
AchieveRx, The Quit Company (Nasdaq: ACHV; QUIT effective November 10, 2026 ; formerly doing business as Achieve Life Sciences, Inc. ) is a late-stage pharmaceutical company with a singular focus on nicotine dependence. AchieveRx's mission is to develop medicine for people who want to quit smoking or vaping. That medicine is cytisinicline, an investigational compound. Three ideas guide the Company: simplicity, science, and second chances, for good.
Latest LNTH
- SEC Form SCHEDULE 13G filed by Lantheus Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
- Amendment: SEC Form SCHEDULE 13D/A filed by Lantheus Holdings Inc.
- PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- SEC Form 10-Q filed by Lantheus Holdings Inc.
- Lantheus Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals